Merck’s New Glaucoma Drug Zioptan Faces Formidable Market Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.